Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes – Module 1 скачать в хорошем качестве

Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes – Module 1

Click here to claim your CME/NCPD credit: https://bit.ly/3RHwjUM Join melanoma authority Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, as he navigates the latest breakthroughs in immunotherapy and targeted treatments transforming outcomes for patients with melanoma. Discover how predictive biomarkers, strategic combination therapies, and personalized treatment sequencing are revolutionizing care across neoadjuvant, adjuvant, and metastatic settings. This podcast is essential listening for oncology professionals seeking evidence-based approaches to combat this challenging disease affecting over 100,000 Americans annually. Follow us here: Facebook   / i3health   Instagram   / i3health   Linkedin   / i3health   Soundcloud   / i3-health   X   / i3health   Click here to listen to module 2 of this podcast series:    • Melanoma in Minutes: Evidence-Driven Care ...   STATEMENT OF NEED Melanoma is one of the most prevalent cancers globally, accounting for over 100,000 new cases and over 8,000 deaths in the United States per year (SEER, 2024). In recent years, the advent of immunotherapy and targeted therapies has revolutionized the treatment of melanoma, improving patient outcomes across the neoadjuvant, adjuvant, and metastatic settings (Chan & Corrie, 2024; NCCN, 2025). In order to optimize the use of these novel therapies, it is vital for members of the interdisciplinary care team to maintain a working knowledge of predictive biomarkers, emerging data on combination therapies, and treatment selection and sequencing approaches that can be personalized for individual patients. In Module 1 of this podcast, Michael A. Davies, MD, PhD, Professor and Chairman of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, will explore how to optimize treatment strategies in melanoma. DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services. Relevant financial relationships exist between the following individuals and ineligible companies: The i3 Health planners, reviewers, and managers have nothing to disclose. Michael A. Davies, MD, PhD, discloses that he has served on an advisory board or panel for ABM, Apexigen, Bristol Myers Squibb, Eisai, Iovance, Novartis, Nurix, Pfizer, Replimune, and Roche; and that he has received grants/research support from ABM, Lead Pharma, and Pfizer. i3 Health has mitigated all relevant financial relationships. #MelanomaCare #Immunotherapy #TargetedTherapies #CancerCare #OncologyEducation #MelanomaResearch #PersonalizedMedicine #Biomarkers #OncologyInnovation #PatientOutcomes